CV Risk with Etoricoxib vs. Diclofenac
Cardiovascular outcomes with the traditional NSAID diclofenac and the still-unapproved selective COX-2 inhibitor etoricoxib were compared by researchers who pooled results from three non–placebo-controlled randomized trials.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)